SNCA and amyotrophic lateral sclerosis: The ALS-FTD case presented Aβ (Phase II of Thal staging and CERAD A criteria) and AT8 immunoreactivity in the hippocampus and entorhinal cortex considered stage I/II of Braak's Classification for Alzheimer's disease (AD).15 Both cases presented non-immunoreactivity for α-synuclein.